Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies

P Pierre Boulard (CEPR, U1100 Inserm, Université de Tours, Tours, France) H Hervé Watier (CEPR, U1100 Inserm, Université de Tours, Tours, France) M Marion Ferreira

Article Details

Volume / Issue Vol. 44, Issue 14
Published May 10, 2026
Pages 1280-1282
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (3)

P

Pierre Boulard

CEPR, U1100 Inserm, Université de Tours, Tours, France

H

Hervé Watier

CEPR, U1100 Inserm, Université de Tours, Tours, France

M

Marion Ferreira